Skip to main navigation Skip to search Skip to main content

Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review

  • Obinna I. Ekwunife
  • , Andreas Gerber Grote
  • , Christoph Mosch
  • , James F. O'Mahony
  • , Stefan K. Lhachimi
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
  • Witten/Herdecke University
  • Trinity College Dublin
  • Leibniz Institute for Prevention Research and Epidemiology
  • University of Bremen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Cervical cancer poses a huge health burden, both to developed and developing nations, making prevention and control strategies necessary. However, the challenges of designing and implementing prevention strategies differ for low- and middle-income countries (LMICs) as compared to countries with fully developed health care systems. Moreover, for many LMICs, much of the data needed for decision analytic modelling, such as prevalence, will most likely only be partly available or measured with much larger uncertainty. Lastly, imperfect implementation of human papillomavirus (HPV) vaccination may influence the effectiveness of cervical cancer prevention in unpredictable ways. This systematic review aims to assess how decision analytic modelling studies of HPV cost-effectiveness in LMICs accounted for the particular challenges faced in such countries. Specifically, the study will assess the following: (1) whether the existing literature on cost-effectiveness modelling of HPV vaccines acknowledges the distinct challenges of LMICs, (2) how these challenges were accommodated in the models, (3) whether certain parameters systemically exhibited large degrees of uncertainty due to lack of data and how influential were these parameters on model-based recommendations, and (4) whether the choice of modelling herd immunity influences model-based recommendations, especially when coverage of a HPV vaccination program is not optimal. Methods: We will conduct a systematic review to identify suitable studies from MEDLINE (via PubMed), EMBASE, NHS Economic Evaluation Database (NHS EED), EconLit, Web of Science, and CEA Registry. Searches will be conducted for studies of interest published since 2006. The searches will be supplemented by hand searching of the most relevant papers found in the search. Studies will be critically appraised using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement checklist. We will undertake a descriptive, narrative, and interpretative synthesis of data to address the study objectives. Discussion: The proposed systematic review will assess how the cost-effectiveness studies of HPV vaccines accounted for the distinct challenges of LMICs. The gaps identified will expose areas for additional research as well as challenges that need to be accounted for in future modelling studies. Systematic review registration: PROSPERO CRD42015017870 .

Original languageEnglish
Article number68
JournalSystematic Reviews
Volume4
Issue number1
DOIs
StatePublished - May 12 2015

Keywords

  • Cost-effectiveness analysis
  • Low- and middle-income countries
  • Mass vaccination
  • Papillomavirus vaccines
  • Uterine cervical neoplasm

Fingerprint

Dive into the research topics of 'Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review'. Together they form a unique fingerprint.

Cite this